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guideline for blood pressure management. A 2014 expert panel recommended increasing the blood pressure targets for
patients age 60 years and older, as well as those with diabetes or chronic kidney disease.
OBJECTIVES The purpose of this study was to examine the effect of the 2014 expert panel blood pressure manage-
ment recommendations on patients managed in U.S. ambulatory cardiovascular practices.
METHODS Using the National Cardiovascular Data Registry PINNACLE Registry, we assessed the proportion of patients
who met the 2003 and 2014 panel recommendations, highlighting the populations of patients for whom the blood
pressure goals changed.
RESULTS Of 1,185,253 patients in the study cohort, 706,859 (59.6%) achieved the 2003 JNC-7 goals. Using the 2014
recommendations, 880,378 (74.3%) patients were at goal. Among the 173,519 (14.6%) for whom goal achievement changed,
40,323 (23.2%) had a prior stroke or transient ischemic attack, and 112,174 (64.6%) had coronary artery disease. In addition,
the average Framingham risk score in this group was 8.5  3.2%, and the 10-year ASCVD risk score was 28.0  19.5%.
CONCLUSIONS Among U.S. ambulatory cardiology patients with hypertension, nearly 1 in 7 who did not meet JNC-7
recommendations would now meet the 2014 treatment goals. If the new recommendations are implemented in clinical
practice, blood pressure target achievement and cardiovascular events will need careful monitoring, because many
patients for whom the target blood pressure is now more permissive are at high cardiovascular risk. (J Am Coll
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2197AB BR E V I A T I O N S
AND ACRONYM S
ASCVD = atherosclerotic
cardiovascular disease
JNC = Joint
National Committee
NCDR = National
Cardiovascular Data Registry
PINNACLE = Practice
Innovation andT he treatment of hypertension is a corner-stone for the prevention of stroke, acute cor-onary events, chronic heart failure, and
kidney disease. Clinicians rely on national clinical
practice guidelines for recommendations on whom
to treat, when to treat, to what goals, and with what
medications. This guidance is particularly important,
because of the need to balance the beneﬁts of cardio-
vascular risk reduction with the costs and potential
complications of therapy.SEE PAGE 2204
Clinical Excellence
TIA = transient ischemic attackIn 2003, the Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure (JNC-7) was
widely implemented by the medical community
(1). This report established blood pressure goals
of <140/90 mm Hg for the general population
and <130/80 mm Hg for patients with diabetes and/
or chronic kidney disease. A follow-up Eighth Joint
National Committee (JNC-8) guideline was initially
drafted with funding from the National Heart, Lung,
and Blood Institute. The National Heart, Lung, and
Blood Institute ultimately decided not to proceed
with the updated guideline, instead focusing on
research and providing support for professional
societies to write their own advisories (2). However,
the expert panel members who were initially
appointed to JNC-8 chose to independently publish
their recommendations. The primary difference be-
tween JNC-7 guidelines and the 2014 panel recom-
mendations was the raising of some of the blood
pressure treatment targets (3), including revised
targets of <150/90 mm Hg for patients age 60 years
and older and <140/90 mm Hg for those with dia-
betes and/or chronic kidney disease.
The 2014 expert panel report represents a major
shift in the treatment of hypertension, and concern
has been expressed about the public health impact
of these less aggressive recommendations on efforts
to prevent cardiovascular disease. Despite the sub-
stantial improvements in cardiovascular disease mor-
bidity and mortality in the United States over the
past few decades, only 50% of patients with hyper-
tension currently receive treatment; thus, critics—
including some members of the JNC-8 panel writing
group itself—argue that the 2014 panel recommen-
dations could slow, halt, or even reverse these gains
(4), especially among at-risk patient groups, such as
elderly women and African Americans (5). One recent
analysis of a U.S. population survey estimated that
5.8 million fewer patients would require blood pres-
sure treatment according to the new report (6).
Whereas those data extrapolated the potential effectof the 2014 panel recommendations in the
general population, we sought to understand
the potential effect on national U.S. cardio-
vascular practice, using data from the Na-
tional Cardiovascular Data Registry (NCDR)
Practice Innovation and Clinical Excellence
(PINNACLE) clinical registry program. This
study assessed the proportion of patients
managed in cardiovascular outpatient prac-
tices meeting the 2003 JNC-7 guideline and
the 2014 panel recommendations and char-
acterized the patients for whom the blood
pressure targets changed under the new
recommendations.
METHODS
DATA SOURCE. The NCDR PINNACLE Registry served
as the study data source. Cardiology practices
voluntarily participate in and submit data to the
PINNACLE Registry as part of a national ofﬁce-based
cardiovascular quality improvement program (7,8).
The data are collected at the point of care through
either a paper chart abstraction form or a validated
electronic health record mapping algorithm designed
to comprehensively capture required data elements.
These data elements include demographics, insur-
ance status, and detailed clinical information, in-
cluding symptoms, medical conditions, vital signs,
medications, and laboratory values. Registry data
quality assurance is maintained through rigorous data
deﬁnitions, standard data collection and trans-
mission, and periodic data quality checks (9,10).
STUDY POPULATION. We identiﬁed all patients age
18 years or older with a diagnosis of hypertension
with clinical encounters in the PINNACLE Registry
version 1.2 between January 1, 2008, and December
31, 2012. A diagnosis of hypertension was deter-
mined through a chart notation of the diagnosis, a
measured systolic blood pressure >140 mm Hg, or a
diastolic blood pressure >90 mm Hg. In addition, we
performed a sensitivity analysis by limiting the
population to those patients who met blood pressure
criteria on 2 or more occasions. We excluded pa-
tients with missing blood pressure measurements
and those with implausible diabetes mellitus history
data, presumably reﬂecting data-entry errors.
CLINICAL OUTCOMES AND CHARACTERISTICS. The
primary study outcome measure was whether pa-
tients with hypertension would meet the 2003 JNC-7
guidelines and/or the 2014 panel treatment goal rec-
ommendations. Patients met the 2003 JNC-7 guide-
lines if they had a blood pressure of <140/90 mm Hg
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tus. For comparison purposes to the 2014 panel rec-
ommendations, we also speciﬁcally assessed patients
age 60 years and older who met a blood pressure goal
of <140/90 mm Hg. Patients met the 2014 panel
recommendations if they had a blood pressure of
<140/90 mm Hg if they were age 18 to 59 years or
had diabetes mellitus at any age, and <150/90 mm Hg
if they were age 60 years or older. We were unable to
assess for a history of chronic kidney disease, because
such data were not recorded in the PINNACLE Reg-
istry version 1.2. If a patient had multiple clinical
encounters during the study period, then the most
recent blood pressure measurement was used. Sensi-
tivity analyses were performed using the ﬁrst blood
pressure measurement and an average of blood
pressure measurements.
Patients were classiﬁed as having diabetes mellitus
if they had a clinical diagnosis of diabetes mellitus,
a hemoglobin A1c $6.5%, a fasting blood glucose
$126 mg/dl, or any blood glucose of $200 mg/dl.
Patients were designated as having coronary artery
disease if they had a clinical diagnosis of coronary
artery disease or if they had a prior history of coro-
nary artery bypass surgery or percutaneous coronary
intervention. We calculated 10-year Framingham
risk scores (11) and 10-year atherosclerotic cardio-
vascular disease (ASCVD) risk scores using the Pooled
Cohorts Equation in the 2013 American College of
Cardiology and American Heart Association Guideline
on the Assessment of Cardiovascular Risk (12,13). We
also assessed the antihypertensive medication classes
that patients were prescribed, including diuretics,
angiotensin-converting enzyme inhibitors, angio-
tensin receptor blockers, beta-blockers, and calcium-
channel blockers.
STATISTICAL ANALYSIS. The analyses performed
were descriptive of patients with various character-
istics meeting the 2003 JNC-7 and the 2014 panel
recommendations. Patients with diabetes mellitus
were categorized accordingly and were not included
in the age categories. We ﬁrst described the de-
mographic and clinical characteristics of patients
achieving recommended goals, including their pre-
scribed medications. We then assessed the patients
who met the 2014 panel recommendations but
did not meet the 2003 JNC-7 guidelines. These pa-
tients had diabetes mellitus and blood pressure
$130/80 mm Hg and <140/90 mm Hg, or, if age
60 years and older, a blood pressure $140/90 mm Hg
and <150/90 mm Hg. All analyses were per-
formed with SAS version 9.3 (SAS Institute, Cary,
North Carolina).RESULTS
The PINNACLE Registry included data on 1,711,326
patients from 2008 to 2012. Among the 1,344,526
patients with hypertension, 1,699 were excluded
because they were <18 years of age, 39,345 were
excluded because they lacked blood pressure mea-
surements, and 118,229 were excluded because of
practices reporting implausible diabetes rates (0.1%,
2.9%, and 8.8% of the total population with reported
hypertension, respectively). The ﬁnal study popula-
tion consisted of 1,185,253 patients.
In this cohort, 706,859 (59.6%) achieved the 2003
JNC-7 guideline goals and 880,378 (74.3%) achieved
the 2014 panel recommendations, with a population
of 173,519 (14.6%) who met the 2014 recommenda-
tions but not the 2003 guidelines. Because the goal
was the same for patients <60 years of age without
diabetes, 195,200 (68.0%) met both the 2003 gui-
delines and the 2014 recommendations, whereas
among patients 60 years of age and older without
diabetes, 385,779 (66.9%) met the 2003 goals and
466,002 (80.8%) met the 2014 panel recommendation
goals. Among patients with diabetes mellitus, 125,880
(39.2%) met the 2003 guideline goals and 219,176
(68.2%) met the 2014 recommendation goals (Central
Illustration). The characteristics of patients meeting
the 2003 JNC-7 guidelines and the 2014 panel recom-
mendations are described in Table 1 and Online
Table 1. The relative frequency of antihypertensive
drug classes prescribed was similar in these 2 pop-
ulations; beta-blockers were prescribed in >50% of
patients within each group followed by diuretics,
angiotensin-converting enzyme inhibitors, calcium-
channel blockers, and angiotensin receptor blockers
(Table 1).
The characteristics of the 173,519 patients for
whom the recommendations differ are listed in
Table 1. Overall, 112,174 (64.6%) had a coronary artery
disease diagnosis, 93,296 (53.8%) had diabetes mel-
litus, 46,910 (27.0%) had a history of heart failure,
43,984 (25.3%) had a prior myocardial infarction, and
40,323 (23.2%) had a prior stroke or transient ischemic
attack (TIA). In calculating the risk scores, 646,895
patients meeting 2003 JNC-7 guideline goals, 806,314
patients meeting the 2014 panel recommendations,
and 159,419 patients for whom the recommendations
changed were missing data for the 10-year Framing-
ham risk score. There were missing data for the
ASCVD risk score for 551,228 patients meeting 2003
JNC-7 goals, 683,694 patients meeting 2014 panel
recommendations, and 132,466 patients for whom the
recommendations changed. Patients with missing
risk score data were generally younger and had
CENTRAL ILLUSTRATION Effect of the 2014 Expert Panel Recommendations for
Management of High Blood Pressure on PINNACLE Cardiovascular Practices
(A) The percentages of patients meeting blood pressure goals for the 2003 Seventh Report
of the Joint National Committee (JNC-7) and the 2014 Panel Report for all patients, patients
younger than 60 years, patients age 60 years and older, and patients with diabetes. (B) The
10-year Framingham risk score (FRS) and the atherosclerotic cardiovascular disease risk
score (ASCVD) for all patients, patients age 60 years and older, and patients with diabetes.
The blue, red, and green bars represent the patients who met the 2003 JNC-7 recom-
mendations, those who met the 2014 panel report recommendations, and the group who
met the 2014 recommendations but not the 2003 recommendations (Delta), respectively.
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commendations changed with calculable risk scores,
the average Framingham risk score was 8.5  3.2%,
and the 10-year ASCVD risk score was 28.0  19.5%.
By comparison, the patients meeting the 2003 JNC-7
guideline goals and the 2014 panel recommenda-
tion goals had average Framingham risk scores of
4.8  4.0% and 5.5  4.2% and 10-year ASCVD risk
scores of 18.6  16.8% and 20.6  17.8%, respectively
(Central Illustration). The sensitivity analyses yielded
similar results.
DISCUSSION
This analysis conducted in a real-world cardiology
practice clinical registry demonstrates that about
three-quarters of patients with hypertension met the
2014 panel recommended blood pressure goals,
whereas less than two-thirds met the 2003 JNC-7
guideline goals. Among those eligible for treatment
who did not meet JNC-7 goals, 14.6% would meet the
2014 panel goals, which was similar to a recent na-
tional population analysis that estimated 15.9% (6).
With the more permissive 2014 blood pressure tar-
gets, patients meeting the new goals had signiﬁcantly
higher cardiovascular risk than those meeting the
2003 guidelines. Speciﬁcally, the patients for whom
the recommendations changed had an average
10-year risk of myocardial infarction or death of
8.5%, and, when stroke risk was included, it rose to
28%. The 2014 panel recommendations are based
on randomized-controlled trial data. However, if
these recommendations are adopted by practitioners
treating real-world populations of high-risk patients
such as those in this study, close monitoring, par-
ticularly with clinical registries, will be necessary to
ensure that improvements in cardiovascular event
rates, particularly stroke, do not reverse course.
An estimated 78 million Americans have hyper-
tension, representing 1 in every 3 adults overall and 2
in every 3 adults age 60 years and older (14). Begin-
ning in the 1970s, substantial public health and clin-
ical efforts have taken hold, with improvements in
blood pressure awareness, treatment, and control.
Hypertension control improved from 27.3% in 1988
to 1994 to 50.1% in 2007 to 2008, although substan-
tial opportunities clearly still exist to further improve
that risk factor control (15). Coincident with this
improvement in blood pressure control and control
of other risk factors has been a strong steady decline
in cardiovascular morbidity and mortality. This
association is especially clear with stroke, where
an almost linear epidemiologic relationship exists
between blood pressure and stroke risk (16). TheUnited States has seen a nearly 4-fold reduction in
stroke deaths with age-adjusted stroke mortality rate,
decreasing from 88 per 100,000 in 1950 to 23 per
100,000 in 2010 (16).
The 2014 panel recommendations concluded that
the existing randomized-controlled trial evidence
was insufﬁcient to support a systolic blood pressure
goal of 140 mm Hg in people age 60 years and older,
unless they were already tolerating such treatment,
and thus raised the goal to 150 mm Hg. The epide-
miologic association between improved population
blood pressure control and decreased cardiovascular
morbidity and mortality is strong, and the clinical
trials demonstrating the beneﬁt of treating high
blood pressure are convincing. In a meta-analysis
TABLE 1 Descriptive Characteristics of Patients Meeting the 2003 JNC-7 Recommendations, Those Meeting the 2014 Panel Report Recommendations, and Those Patients for Whom the Recommendations Changed
Age <60 yrs Age $60 yrs Diabetes Total
Meeting 2003
JNC-7 and 2014
Panel Report Goals
Meeting 2003
JNC-7 Goal
Meeting 2014
Panel Report Goal
Meeting 2014 Panel
Report Goal But Not
2003 JNC-7 Goal
Meeting 2003
JNC-7 Goal
Meeting 2014
Panel Report Goal
Meeting 2014 Panel
Report Goal But Not
2003 JNC-7 Goal
Meeting 2003
JNC-7 Goal
Meeting 2014
Panel Report Goal
Meeting 2014 Panel
Report Goal But Not
2003 JNC-7 Goal
Total (N ¼ 1,185,253) 195,200 (68.0) 385,779 (66.9) 466,002 (80.8) 80,223 (6.8) 125,880 (39.2) 219,176 (68.2) 93,296 (7.9) 706,859 (59.6) 880,378 (74.3) 173,519 (14.6)
Demographics
Race
White 80,955 (85.4) 203,055 (92.4) 244,782 (92.4) 41,727 (92.4) 61,924 (86.1) 106,043 (85.0) 44,119 (83.6) 345,934 (89.5) 431,780 (89.1) 85,846 (87.7)
Black 11,272 (11.9) 12,172 (5.5) 14,893 (5.6) 2,721 (6.0) 8,026 (11.2) 15,423 (12.4) 7,397 (14.0) 31,470 (8.1) 41,588 (8.6) 10,118 (10.3)
Other 2,564 (2.7) 4,474 (2.0) 5,174 (2.0) 700 (1.6) 1,952 (2.7) 3,229 (2.6) 1,277 (2.4) 8,990 (2.3) 10,967 (2.3) 1,977 (2.0)
Sex
Male 97,493 (50.0) 197,572 (51.3) 234,954 (50.5) 37,382 (46.7) 69,972 (55.7) 120,742 (55.2) 50,770 (54.5) 365,037 (51.7) 453,189 (51.5) 88,152 (50.9)
Female 97,442 (50.0) 187,676 (48.7) 230,419 (49.5) 42,743 (53.3) 55,722 (44.3) 98,120 (44.8) 42,398 (45.5) 340,840 (48.3) 425,981 (48.5) 85,141 (49.1)
Age, yrs 47.5  9.8 74.3  9.1 74.4  9.0 74.7  8.8 68.4  12.7 67.4  12.7 66.1  12.7 65.9  15.3 66.7  14.8 70.1  11.9
Clinical characteristics
Prior stroke/TIA 40,187 (20.6) 85,099 (22.1) 100,976 (21.7) 15,877 (19.8) 30,935 (24.6) 55,381 (25.3) 24,446 (26.2) 156,221 (22.1) 196,544 (22.3) 40,323 (23.2)
MI history 39,926 (20.5) 101,968 (26.4) 120,456 (25.8) 18,488 (23.0) 38,142 (30.3) 63,638 (29.0) 25,496 (27.3) 180,036 (25.5) 224,020 (25.4) 43,984 (25.3)
CAD 91,444 (46.8) 247,242 (64.1) 294,883 (63.3) 47,641 (59.4) 92,729 (73.7) 157,262 (71.8) 64,533 (69.2) 431,415 (61.0) 543,589 (61.7) 112,174 (64.6)
Recent CABG or PCI 36,506 (18.7) 73,374 (19.0) 87,204 (18.7) 13,830 (17.2) 29,588 (23.5) 50,148 (22.9) 20,560 (22.0) 139,468 (19.7) 173,858 (19.7) 34,390 (19.8)
DM 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 125,880 (100.0) 219,176 (100.0) 93,296 (100.0) 125,880 (17.8) 219,176 (24.9) 93,296 (53.8)
Heart failure 31,885 (16.3) 106,981 (27.7) 124,484 (26.7) 17,503 (21.8) 47,136 (37.4) 76,543 (34.9) 29,407 (31.5) 186,002 (26.3) 232,912 (26.5) 46,910 (27.0)
Framingham risk score, % 2.1  4.6 5.9  2.4 6.4  2.6 8.5  2.4 7.5  3.8 8.0  3.8 8.5  3.8 4.8  4.0 5.5  4.2 8.5  3.2
10-year ASCVD risk, % 3.6  3.3 21.0  15.4 22.1  16.1 27.9  18.2 26.6  19.2 27.2  19.7 28.0  20.4 18.6  16.8 20.6  17.8 28.0  19.5
Values are n (%) or mean  SD.
ASCVD ¼ atherosclerotic cardiovascular disease; CABG ¼ coronary artery bypass surgery; CAD ¼ coronary artery disease; DM ¼ diabetes mellitus; HTN ¼ hypertension; JNC ¼ Joint National Committee; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary
intervention; TIA ¼ transient ischemic attack.
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2201of 72 randomized controlled trials, Law et al. (17)
showed that lowering systolic blood pressure by
10 mm Hg and diastolic blood pressure by 5 mm Hg
reduced coronary heart disease events by 22% and
strokes by 41%, including a 15% reduction in coronary
heart disease events and a 23% reduction in strokes
in trials where the pre-treatment systolic blood
pressure was 140 to 159 mm Hg. Evidence exists
for treating to a systolic blood pressure target of
about 140 mm Hg in both younger and older in-
dividuals (4,18–20). However, when speciﬁcally us-
ing randomized-controlled trial evidence to address
the question of a blood pressure target for people
older than age 60 years, the 2014 panel members
felt the data did not demonstrate additional beneﬁt
to a systolic blood pressure goal of <140 mm Hg
(3,21,22).
That recommendation was considered controver-
sial, and a faction of the writing group felt strongly
enough to publish their perspective (4). A minority
of the panel dissented with that recommendation,
because they thought there was insufﬁcient evidence
of harm with the existing goal to make the change,
especially in light of the signiﬁcant gains experienced
in cardiovascular morbidity and mortality. These
dissenting panel members felt that the burden of
evidence was on demonstrating a clear beneﬁt to
increasing the blood pressure goal and that such
evidence was inadequate (4). Our study lends support
to these concerns by demonstrating the substantial
cardiovascular risk in the patients for whom the rec-
ommendations change and highlights the uncertainty
of how the new recommendations will ultimately
affect real-world patients.
IMPLICATIONS. In light of the concerns about loos-
ening the blood pressure goal for older patients
and those with diabetes mellitus, our study provides
a detailed perspective on patients receiving care
in ambulatory cardiology practices. Our ﬁndings
demonstrate that these patients, particularly those
for whom the blood pressure goals changed, are at
baseline substantial risk of coronary heart events and
stroke. Several studies have speciﬁcally examined
blood pressure lowering in older adults. The SHEP
(Systolic Hypertension in the Elderly Program) trial,
in which the mean age was 72 years, showed that a
reduction in mean systolic blood pressure from 155
to 143 mm Hg was associated with a 32% reduction
in cardiovascular events at 5 years (18). The HYVET
(Hypertension in the Very Elderly Trial) showed a
similar result in patients with a mean age of 83.6
years, in whom a reduction in mean systolic blood
pressure from 158.5 to 143.5 mm Hg resulted in a
34% reduction in cardiovascular events at 2 years(19). Although these SHEP and HYVET ﬁndings
show achieved blood pressures, rather than the goal
blood pressures in the 2014 panel recommendations,
the results inform how measured blood pressure
changes are associated with reductions in cardiovas-
cular events.
Using these randomized controlled trial risk
reduction results and the 10-year ASCVD risk of
27.9% estimated for the older population in the
PINNACLE Registry for whom the adequacy of
blood pressure control using recommended targets
changed, treating patients from a systolic blood
pressure of about 150 to about 140 mm Hg is estimated
to result in a 9- to 10-point 10-year ASCVD absolute
risk reduction to 19.0% using the SHEP data and 18.4%
using HYVET data. This is equivalent to a number-
needed-to-treat over 10 years of 10 to 11 patients to
prevent 1 cardiovascular event. This estimate is
consistent with national projections in a similar at-
risk population that a 12 mm Hg reduction over 10
years from a baseline systolic blood pressure of 140 to
159 mm Hg would result in a number-needed-to-treat
of 11 patients to prevent a cardiovascular event (23).
Using these data about patients age 60 years and
older, treatment of the more than 80,000 older pa-
tients in our study population affected by the change
in targets to a systolic blood pressure goal of 140
mm Hg could potentially avert approximately 8,000
cardiovascular events over 10 years.
These estimates of averted cardiovascular events
do not account for potential adverse treatment effects
or the costs of therapy. However, they highlight
the substantial absolute risk of patients affected by
the 2014 panel report recommendations and the
potential for lost treatment beneﬁt. On a national
scale, 1 analysis estimates that 13.5 million patients
with hypertension who had previously not met JNC-7
guideline goals would now meet treatment goals
in 2014 recommendations (6). Our study population
from cardiology practices has higher risk than the
general population, yet represents an important
cohort with profound implications for the broader
U.S. population.
STUDY LIMITATIONS. First, our study population is
restricted to U.S. cardiology practices that participate
in the PINNACLE Registry. The population in our
study has greater cardiovascular comorbidity and
better blood pressure control than a general popula-
tion sample (14). Although this can be construed as
a weakness, we believe that our study provides
important insights more broadly to similarly high-risk
real-world individuals with hypertension. Second,
there may be variability in the measurement of
blood pressure. Some PINNACLE Registry patients
PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE:
The 2014 expert panel recommends higher blood
pressure targets than the 2003 JNC-7 report, so fewer
patients meet criteria for treatment of high blood
pressure.
TRANSLATIONAL OUTLOOK: Clinical outcomes
studies are needed to gauge the effect of application
of the 2014 expert panel recommendations on cardiac
events in well-deﬁned patient populations.
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2202only have a single blood pressure measurement,
which may not be reﬂective of their overall blood
pressure pattern. Our sensitivity analysis of using
more than 1 blood pressure measurement yielded
similar results. Third, the PINNACLE Registry obtains
data directly from clinical care processes, mostly
from electronic health records rather than special-
ized research abstracters, and thus, data collection
may be more incomplete. Last, missing data may
have led to an overestimation of the 10-year Fra-
mingham and ASCVD risk scores. For example, the
average age was 62.4 and 64.0 years, the rate of
diabetes mellitus was 19.1% and 23.8%, and prior
stroke or TIA occurred in 11.8% and 15.9% of patients
missing and not missing Framingham risk scores,
respectively. Similarly, the average age was 65.4
and 68.0 years, the rate of diabetes mellitus was
25.8% and 31.8%, and prior stroke or TIA occurred in
21.9% and 22.8% of patients missing and not missing
ASCVD risk scores, respectively. Even though the
risk scores may be overestimated, the fundamen-
tal ﬁnding of elevated cardiovascular risk in this
population is unchanged.
CONCLUSIONS
This study found that 14.6% of patients in ambula-
tory cardiology practices who previously failed to
meet the 2003 JNC-7 guidelines recommendations
now meet the 2014 panel recommendations. These
patients have high rates of prior cardiovascular dis-
ease and high 10-year risk of cardiovascular events.
With the several other blood pressure management
guidelines available, it remains to be seen howpractice patterns change based on the 2014 panel
recommendations. Some of that uptake may be
inﬂuenced by whether the 2014 panel recom-
mendations are incorporated into performance mea-
sures, public reporting, and value-based purchasing
programs. Given the size and underlying cardiovas-
cular risk of the population affected by the changes in
the 2014 panel recommendations, close monitoring
will be required to assess changes in practice pat-
terns, follow blood pressure control, and, impor-
tantly, determine any changes in cardiovascular
morbidity and mortality.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
William B. Borden, Department of Medicine, George
Washington University, 2150 Pennsylvania Avenue,
NW, Washington, DC 20037. E-mail: wborden@mfa.
gwu.edu.RE F E RENCE S1. Chobanian AV, Bakris GL, Black HR, et al. The
seventh report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure: the JNC 7 Report. JAMA
2003;289:2560–72.
2. Gibbons GH, Shurin SB, Mensah GA, et al.
Refocusing the agenda on cardiovascular guide-
lines: an announcement from the National Heart,
Lung, and Blood Institute. Circulation 2013;128:
1713–5.
3. James PA, Oparil S, Carter BL, et al. 2014
evidence-based guideline for the management of
high blood pressure in adults: report from the
Panel Members Appointed to the Eighth Joint Na-
tional Committee (JNC 8). JAMA 2013;1097:1–14.
4. Wright JT, Fine LJ, Lackland DT, et al. Evidence
supporting a systolic blood pressure goal of less
than 150 mm Hg in patients aged 60 years or
older: the minority view. Ann Intern Med 2014;
160:499–503.
5. Krakoff LR, Gillespie RL, Ferdinand KC, et al.
2014 hypertension recommendations from theEighth Joint National Committee panel members
raise concerns for elderly black and female pop-
ulations. J Am Coll Cardiol 2014;64:394–402.
6. Navar-Boggan AM, Pencina MJ, Williams K,
et al. Proportion of US adults potentially affected
by the 2014 hypertension guideline. JAMA 2014;
311:1424–9.
7. Chan PS, Oetgen WJ, Buchanan D, et al. Car-
diac performance measure compliance in out-
patients. The American College of Cardiology
and National Cardiovascular Data Registry’s
PINNACLE (Practice Innovation And Clinical
Excellence) Program. J Am Coll Cardiol 2010;
56:8–14.
8. Chan PS, Oetgen WJ, Spertus JA. The Improving
Continuous Cardiac Care (IC3) Program and out-
patient quality improvement. Am J Med 2010;123:
217–9.
9. Messenger JC, Ho KK, Young CH, et al. The
National Cardiovascular Data Registry (NCDR) data
quality brief: the NCDR Data Quality Program in
2012. J Am Coll Cardiol 2012;60:1484–8.10. Masoudi FA, Ponirakis A, Yeh RW, et al. Car-
diovascular care facts: a report from the National
Cardiovascular Data Registry: 2011. J Am Coll
Cardiol 2013;62:1931–47.
11. Wilson PW, D’Agostino RB, Levy D, et al.
Prediction of coronary heart disease using
risk factor categories. Circulation 1998;97:
1837–47.
12. Goff DC, Lloyd-Jones DM, Bennett G, et al.
2013 ACC/AHA guideline on the assessment of
cardiovascular risk: a report of the American Col-
lege of Cardiology/American Heart Association
Task Force on Practice Guidelines. J Am Coll
Cardiol 2014;63:2935–59.
13. American Heart Association. 2013 pre-
vention guidelines tools: CV Risk Calculator.
2013. Available at: https://my.americanheart.org/
professional/StatementsGuidelines/Prevention
Guidelines/Prevention-Guidelines_UCM_457698_
SubHomePage.jsp. Accessed April 1, 2014.
14. Go AS, Mozaffarian D, Roger VL, et al. Heart
disease and stroke statistics—2014 update: a
J A C C V O L . 6 4 , N O . 2 1 , 2 0 1 4 Borden et al.
D E C E M B E R 2 , 2 0 1 4 : 2 1 9 6 – 2 0 3 Impact of Blood Pressure Panel Recommendations
2203report from the American Heart Association.
Circulation 2014;129:e28–292.
15. Egan BM, Zhao Y, Axon RN. US trends in
prevalence, awareness, treatment, and control
of hypertension, 1988–2008. JAMA 2010;303:
2043–50.
16. Lackland DT, Roccella EJ, Deutsch AF, et al.
Factors inﬂuencing the decline in stroke mortality:
a statement from the American Heart Association/
American Stroke Association. Stroke 2014;45:
315–53.
17. Law MR, Morris JK, Wald NJ. Use of blood
pressure lowering drugs in the prevention of car-
diovascular disease: meta-analysis of 147 rando-
mised trials in the context of expectations from
prospective epidemiological studies. BMJ 2009;
338:b1665.18. SHEP Cooperative Research Group. Preven-
tion of stroke by antihypertensive drug treatment
in older persons with isolated systolic hyperten-
sion: ﬁnal results of the Systolic Hypertension in
the Elderly Program (SHEP). JAMA 1991;265:
3255–64.
19. Beckett NS, Peters R, Fletcher AE, et al.
Treatment of hypertension in patients 80 years of
age or older. N Engl J Med 2008;358:1887–98.
20. Liu L, Zhang Y, Liu G, et al. The Felodipine
Event Reduction (FEVER) Study: a randomized
long-term placebo-controlled trial in Chinese hy-
pertensive patients. J Hypertens 2005;23:2157–72.
21. The JATOS Study Group. Principal results of
the Japanese Trial to Assess Optimal Systolic
Blood Pressure in Elderly Hypertensive Patients
(JATOS). Hypertens Res 2008;31:2115–27.22. Ogihara T, Saruta T, Rakugi H, et al. Target
blood pressure for treatment of isolated systolic
hypertension in the elderly: Valsartan in Elderly
Isolated Systolic Hypertension Study. Hypertens
2010;56:196–202.
23. Ogden LG, He J, Lydick E, et al. Long-
term absolute beneﬁt of lowering blood pres-
sure in hypertensive patients according to the
JNC VI risk stratiﬁcation. Hypertension 2000;35:
539–43.
KEY WORDS CAD, guidelines,
hypertension, prevention, stroke
APPENDIX For a supplemental table, please
see the online version of this article.
